Thymosin Alpha-1 + BPC-157
The best-evidenced compound on this site, and its largest trial found nothing.
Thymosin alpha-1 is an approved drug in more than 35 countries with decades of trials behind it. It is paired with BPC-157 to cover immunity and tissue repair at once. In 2025 a 1,106-patient double-blind trial tested it in sepsis and found no benefit, and the authors said that result should outweigh the earlier positive ones.
Repair the tissue, support the system repairing it.
The pairing is aimed at people who are both run down and recovering from something. Gut problems after antibiotics, repeated infections alongside an injury that will not settle, or the general sense that immunity has slipped.
Thymosin alpha-1 is chosen because it is the one compound here with a real regulatory history. It is an approved drug in more than 35 countries, which nothing else on this site can say except the GLP-1 drugs and PT-141.
BPC-157 covers the repair side, and its oldest documented effects were all gastrointestinal, which is why this pairing shows up most often around gut problems.
One roundup names this the strongest evidence-backed immune and repair combination available.[7] That claim rests entirely on the first half, and on evidence that has changed.
Four benefits, and how well each one holds up.
One proven row, and it is a viral clearance rate in liver disease. The bottom row is the one people are buying.
Three questions, answered before anything else.
Bigger, better designed, and negative.
Thymosin alpha-1's reputation in sepsis rests on ETASS, a 2013 trial in Critical Care. It enrolled 361 severe sepsis patients across six Chinese intensive care units and was single-blind, meaning patients did not know what they received but the researchers did.[3]
TESTS, published in the BMJ in January 2025, was built to settle the question properly.[8]
The authors of the larger trial were explicit about how to read the pair. They concluded there was no clear evidence that thymosin alpha-1 reduces 28-day mortality in sepsis. An adequately powered double-blind result, they wrote, should weigh more heavily than earlier positive signals from smaller trials.[3]
That is how medicine is supposed to work. Vendor pages have not caught up. Sepsis still appears in lists of what thymosin alpha-1 is approved and proven for.
It does not undo the hepatitis evidence, which is separate, older and still sound. It does mean the phrase "trials covering thousands of patients" now includes the largest of them finding nothing.
Two qualifications belong with that. The same research group published a meta-analysis in September 2025 noting that elderly and diabetic subgroups in TESTS showed potential effects.[9] Subgroup findings in a negative trial are a reason to run another study rather than a reason to act.
Every trial in that meta-analysis was conducted in China, which its authors flag as a limit on how far the findings generalise.[9] That applies to the positive hepatitis results as much as the negative sepsis one.
Hepatitis B, and a mechanism worth understanding.
Thymosin alpha-1 is approved as Zadaxin in more than 35 countries, chiefly for chronic hepatitis B and C and for immune deficiency states.[1] China is the largest market, where it is also widely used as immune support during chemotherapy.
Multiple randomised trials found it improved viral clearance in chronic hepatitis B, with one reporting a virological response rate of 40.6 percent against 9.4 percent in controls.[2] Combined with interferon it consistently outperformed interferon alone.
The mechanism is immune modulation rather than direct antiviral action. It activates toll-like receptor 9 in dendritic cells, which pushes T helper cell function, natural killer cell activity and antibody responses.[4]
It is described as working in both directions, strengthening a weak immune response and dampening an overactive one.[5] That is an appealing property and it is also the kind of claim that is hard to test in someone who is well.
A 2024 review of the human trials found it safe and well tolerated across every studied indication.[1] Safety is the part of its record that has held up best.
The most popular peptide with no published human trial.
BPC-157 came out of human stomach fluid in the early 1990s, and its first documented effects were all gastrointestinal. It is the most widely sold research peptide on the market, with 207 in-stock listings in our data.[6]
It reached a Phase 2 trial in ulcerative colitis, run in Croatia under the designation PL 14736. The results have never been published. The gut pair page covers that in full.
So the pairing puts the compound with the strongest regulatory record next to the one with the weakest published record, and that contrast is most of what makes it interesting.
There is a mechanistic argument for combining them. Tissue repair and immune function are connected, and inflammation sits between them. No trial has tested whether pushing both at once does more than pushing either.[7]
Two vials, or a four-compound blend that includes both.
Nobody sells this exact pair premixed. Bought separately the two come to $51.18 at the cheapest in-stock listings.[6]
One vendor does sell a four-compound vial at $115.00 containing BPC-157, GHK-Cu, TB-500 and thymosin alpha-1, which is GLOW with the immune compound added.[6] It states all four amounts, which is better disclosure than most blends manage.
Thymosin alpha-1 is the expensive half and the price spread is wide. Buying separately lets you stop it without losing the repair side, which matters on a pairing where one half has just had its largest trial come back negative.
Approved abroad, restricted here, and that changed recently.
Thymosin alpha-1 has never been approved by the FDA. It is approved in Italy, China, Taiwan, South Korea, Brazil, Argentina and more than thirty other countries, with indications varying by country.[5]
Its US compounding status has a clearer answer than it used to. Following a February 2026 reclassification, thymosin alpha-1 holds Category 2 status under the FDA's 503A bulk substance framework as of April 2026, which means compounding pharmacies may not use it.[4]
That resolves some of the confusion covered on the GHK-Cu pairing page, where five commercial sources gave five different accounts of its legal position.
BPC-157 holds the same Category 2 status. Everything sold online is research chemical material, and neither compound has an approved US label.
What people ask about this stack
Is thymosin alpha-1 the best-evidenced peptide?
Thymosin alpha-1 has the strongest regulatory record of anything covered here, approved in more than 35 countries for hepatitis B and C and immune deficiency. Its hepatitis evidence is solid, with randomised trials reporting viral clearance of 40.6 percent against 9.4 percent in controls. Its sepsis evidence no longer holds. A 1,106-patient double-blind trial published in the BMJ in 2025 found no reduction in 28-day mortality, and the authors said that result should outweigh earlier positive signals from smaller trials.
Why did the sepsis result change?
Better design. The earlier trial enrolled 361 patients across six centres and was single-blind, so researchers knew who was receiving the drug. The 2025 trial enrolled 1,089 across 22 centres and was double-blind and placebo-controlled. No secondary or safety outcome differed either. Larger, better-blinded trials overturning smaller positive ones is a normal and important pattern in medicine.
Does the pairing with BPC-157 have evidence?
None. One evidence review states that no primary source supports a combined gut or immune protocol, that no ideal dosing has been established, and that long-term safety of the combination is unknown. It adds that thymosin alpha-1 findings in a specific disease should not be generalised to a wellness stack, which is the central problem with how this pairing is sold.
Is it legal to get in the US?
Neither compound has FDA approval. Following a February 2026 reclassification, thymosin alpha-1 holds Category 2 status under the FDA 503A bulk substance framework as of April 2026, which means compounding pharmacies may not use it. BPC-157 sits in Category 2 as well. Everything sold online is research chemical material.
What does it cost?
The pair comes to $51.18 at the cheapest in-stock listings, with thymosin alpha-1 at $31.99 and BPC-157 at $19.19. No premixed version of the pair exists, though one vendor sells a four-compound vial at $115.00 containing BPC-157, GHK-Cu, TB-500 and thymosin alpha-1, with all four amounts stated.
Will it help a healthy person's immune system?
Nobody has tested that. Every human trial of thymosin alpha-1 was run in people with a diagnosis: hepatitis, sepsis, cancer, immune deficiency. Its described ability to strengthen a weak immune response and dampen an overactive one is appealing and hard to measure in someone who is well. Compare against the other stacks.
What this page is built on
- 01Zadaxin (thymalfasin) approval and market history. Synthetic 28-amino-acid peptide identical to naturally occurring thymosin alpha-1, approved in over 35 countries for chronic hepatitis B, hepatitis C and immunodeficiency states, never FDA-approved. China the largest market, with use in oncology as immune support during chemotherapy. A 2024 review of human clinical trials found it safe and well tolerated across all studied indications.
- 02Hepatitis B randomised controlled trial reporting a virological response rate of 40.6 percent with thymosin alpha-1 against 9.4 percent in controls at 26 weeks. Multiple trials found improved HBeAg seroconversion and HBV DNA suppression, with thymalfasin plus interferon-alpha outperforming interferon alone.
- 03Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care, 2013;17(1):R8. PMID 23327199, DOI 10.1186/cc11932. 361 patients across six Chinese intensive care units, 181 receiving thymosin alpha-1 and 180 controls.
- 08Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 2025;388:e082583, published 15 January 2025. PMID 39814420, DOI 10.1136/bmj-2024-082583. 1,106 adults with sepsis enrolled across 22 Chinese medical centres, 1,089 in the modified intention-to-treat analysis, 542 on thymosin alpha-1 and 547 on placebo. No reduction in 28-day mortality and no significant difference in any secondary or safety outcome. A correction was published at BMJ 2025;389:r1098.
- 09Gu B, Zhou Y, Nie Y, et al. Efficacy of thymosin alpha-1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology, 2025;15:1673959, published 3 September 2025. DOI 10.3389/fcimb.2025.1673959. From the same research group as both sepsis trials. Notes that TESTS found no mortality reduction or clinical improvement although elderly and diabetic subgroups showed potential effects, and that every included study was conducted in China, which the authors raise as a limit on generalisability. A related earlier review is at PMC5025565.
- 04Thymosin alpha-1 mechanism and US regulatory status. Activation of toll-like receptor 9 in dendritic cells, augmenting T helper cell function, natural killer cell activity and antibody responses to T-cell dependent antigens. Category 2 status under the FDA 503A bulk substance framework as of April 2026, following the February 2026 reclassification. See also trial protocol NCT04428008.
- 05Country-by-country approval status, including Italy since 1995 as an adjuvant for hepatitis B, plus China, Taiwan, South Korea, Brazil and Argentina. Also the source for the description of bidirectional immune modulation, strengthening weak defence and dampening excessive reactions, and for a half-life of about two hours.
- 06Peptide Decoding vendor pricing data, 26 September 2026. Lowest in-stock single-compound listings: thymosin alpha-1 $31.99 across 50 listings, BPC-157 $19.19 across 207. No premixed listing of the pair. One four-compound blend at $115.00 stating 5 mg BPC-157, 50 mg GHK-Cu, 2 mg TB-500 and 3 mg thymosin alpha-1.
- 07Evidence review of the BPC-157 and thymosin alpha-1 pairing. Source for the combined protocol not having been established in controlled human trials, for no primary source supporting a combined gut or immune dosage protocol, for the absence of established dosing and long-term safety, and for the caution that thymosin alpha-1 findings in a specific disease should not be generalised to a wellness stack. Also the source describing this as an evidence-backed immune and repair combination.